Page 73 - Read Online

Financial support and sponsorship 7. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani
Nil. S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V.
Gemcitabine in the treatment of refractory Hodgkin’s disease: results
of a multicenter phase II study. J Clin Oncol 2000;18:2615-9.
Conflicts of interest 8. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, Ruiz
There are no conflicts of interest. J, Heitjan D, Keohan ML, Flamm M, Johnson SA. Gemcitabine for
relapsed or resistant lymphoma. Ann Oncol 2000;11:595-7.
REFERENCES 9. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-
Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd
L, Iglesias J, Meyer R. Gemcitabine, dexamethasone, and cisplatin
1. Armitage JO. A clinical evaluation of the International Lymphoma in patients with recurrent or refractory aggressive histology B-cell
Study Group classification of non-Hodgkin’s lymphoma. Blood non-Hodgkin lymphoma: a phase II study by the National Cancer
1997;89:3909-18. Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer
2. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance 2004;101:1835-42.
series: non-Hodgkin’s lymphoma incidence by histologic subtype 10. Cheson BD, Horning SJ, Coiffler B, Shipp MA, Fisher RI, Connors
in the United States from 1978 through 1995. J Natl Cancer Inst JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F,
2000;92:1240-51. Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO,
3. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Carter W, Hoppe R, Canellos GP. Report of an international workshop
Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma to standardize response criteria for non-Hodgkin’s lymphoma. J Clin
D, Brière J, Moskowitz CH, Schmitz N. Salvage regimens with Oncol 1999;17:1244.
autologous transplantation for relapsed large B-cell lymphoma in the 11. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M,
rituximab era. J Clin Oncol 2010;28:4184-90. Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol
4. Sweetenham JW, Johnson PW. ESHAP chemotherapy for relapsed/ 2013;87:146-71.
refractory non-Hodgkin’s lymphoma. J Clin Oncol 1994;12:2766. 12. Hou Y, Wang HQ, Ba Y. Rituximab, gemcitabine, cisplatin, and
5. Bernell P, Ohm L. Promising activity of gemcitabine in refractory high- dexamethasone in patients with refractory or relapsed aggressive
grade non-Hodgkin’s lymphoma. Br J Haematol 1998;101:203-4. B-cell lymphoma. Med Oncol 2012;29:2409-16.
6. Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, 13. Fan Y, Huang ZY, Luo LH, Yu HF. Efficacy of GDP regimen
Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR. Gemcitabine (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory
as a single agent in the treatment of relapsed or refractory aggressive aggressive non-Hodgkin’s lymphoma: a report of 24 cases. Ai Zheng
non-Hodgkin’s lymphoma. J Clin Oncol 1999;17:3786-92. 2008;27:1222-5.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 2 ¦ February 29, 2016 ¦ 63